Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
2012 · Nucleic Acids Research · 4,154 citations
https://doi.org/10.1093/nar/gks1111
C
Cyril H. Benes
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
688
Papers
31.0K
Citations
74
h-index
133
i10-index
Cyril H. Benes is an academic researcher from Harvard University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & RNA modifications and cancer & Protein Degradation and Inhibitors. The author has an h-index of 74, co-authored 585 publications.
ORCID: 0000-0002-8751-9707Papers by this author
worksA Landscape of Pharmacogenomic Interactions in Cancer
2016 · Cell · 2,158 citations
https://doi.org/10.1016/j.cell.2016.06.017
Effective drug combinations in breast, colon and pancreatic cancer cells
2022 · Nature · 440 citations
https://doi.org/10.1038/s41586-022-04437-2
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
2018 · Cancer Discovery · 409 citations
https://doi.org/10.1158/2159-8290.cd-18-0387
HER2 expression identifies dynamic functional states within circulating breast cancer cells
2016 · Nature · 405 citations
https://doi.org/10.1038/nature19328
BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors
2011 · Cancer Discovery · 277 citations
https://doi.org/10.1158/2159-8290.cd-11-0106
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat